<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The HER2 protein, encoded by the ERBB2 gene, is a molecular target for the treatment of breast and <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> by monoclonal antibodies or <z:chebi fb="0" ids="38637">tyrosine kinase inhibitors</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>While intratumoral <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of ERBB2 amplification is rare in <z:hpo ids='HP_0003002'>breast cancer</z:hpo> it is reported to be frequent in bladder and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>To address the potential <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of the HER2 status in <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>, <z:hpo ids='HP_0002860'>squamous cell carcinomas</z:hpo> and large cell undifferentiated <z:mp ids='MP_0002038'>carcinomas</z:mp> of the lung, 590 tumors were analyzed for HER2 overexpression and ERBB2 amplification using FDA-approved reagents for immunohistochemistry and fluorescence in-situ hybridization (FISH) </plain></SENT>
<SENT sid="3" pm="."><plain>Moderate and strong immunostaining (2+, 3+) was seen in 10% of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>ERBB2 amplification was found in 17 (3%) <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> patients including 10 cases (2%) with high-level amplification forming gene clusters </plain></SENT>
<SENT sid="5" pm="."><plain>ERBB2 amplification was significantly related to histologic subtype and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> grade, resulting in 12% ERBB2 amplified <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in the subgroup of high-grade <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0001425'>Heterogeneity</z:hpo> was analyzed in <z:hpo ids='HP_0000001'>all</z:hpo> highly amplified <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>For this purpose, <z:hpo ids='HP_0000001'>all</z:hpo> available <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue blocks from these patients were evaluated </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0001425'>Heterogeneity</z:hpo> of ERBB2 amplification was found in 4 of 10 tumors as assessed by FISH </plain></SENT>
<SENT sid="9" pm="."><plain>These included two <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with a mixture of low-level and high-level amplification and two <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with non-amplified <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> areas next to regions with high-level ERBB2 amplification </plain></SENT>
<SENT sid="10" pm="."><plain>High-level ERBB2 amplification occurs in a small fraction of <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancers</z:e> with a strong propensity to high-grade <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0001425'>Heterogeneity</z:hpo> of amplification may limit the utility of anti-HER2 therapy in some of these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Further attempts to assess the utility of HER2-targeting therapy in homogeneously amplified <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancers</z:e> appear to be justified </plain></SENT>
</text></document>